1. Home
  2. CDXS vs NXG Comparison

CDXS vs NXG Comparison

Compare CDXS & NXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDXS
  • NXG
  • Stock Information
  • Founded
  • CDXS 2002
  • NXG 2012
  • Country
  • CDXS United States
  • NXG United States
  • Employees
  • CDXS N/A
  • NXG N/A
  • Industry
  • CDXS Major Chemicals
  • NXG
  • Sector
  • CDXS Industrials
  • NXG
  • Exchange
  • CDXS Nasdaq
  • NXG Nasdaq
  • Market Cap
  • CDXS 201.3M
  • NXG 170.5M
  • IPO Year
  • CDXS 2010
  • NXG N/A
  • Fundamental
  • Price
  • CDXS $2.27
  • NXG $48.62
  • Analyst Decision
  • CDXS Buy
  • NXG
  • Analyst Count
  • CDXS 2
  • NXG 0
  • Target Price
  • CDXS $11.00
  • NXG N/A
  • AVG Volume (30 Days)
  • CDXS 1.0M
  • NXG 24.4K
  • Earning Date
  • CDXS 08-07-2025
  • NXG 01-01-0001
  • Dividend Yield
  • CDXS N/A
  • NXG 14.78%
  • EPS Growth
  • CDXS N/A
  • NXG N/A
  • EPS
  • CDXS N/A
  • NXG N/A
  • Revenue
  • CDXS $49,815,000.00
  • NXG N/A
  • Revenue This Year
  • CDXS $12.77
  • NXG N/A
  • Revenue Next Year
  • CDXS $22.12
  • NXG N/A
  • P/E Ratio
  • CDXS N/A
  • NXG N/A
  • Revenue Growth
  • CDXS N/A
  • NXG N/A
  • 52 Week Low
  • CDXS $1.90
  • NXG $30.32
  • 52 Week High
  • CDXS $6.08
  • NXG $42.29
  • Technical
  • Relative Strength Index (RSI)
  • CDXS 48.16
  • NXG 55.60
  • Support Level
  • CDXS $2.20
  • NXG $48.65
  • Resistance Level
  • CDXS $2.51
  • NXG $51.41
  • Average True Range (ATR)
  • CDXS 0.14
  • NXG 1.11
  • MACD
  • CDXS -0.00
  • NXG -0.11
  • Stochastic Oscillator
  • CDXS 42.65
  • NXG 38.14

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

About NXG NXG NextGen Infrastructure Income Fund of Beneficial Interest

Cushing NextGen Infrastructure Income Fund is a closed-end investment management company. Its investment objective is to seek a high total return with a focus on current income. The Fund invests at least 80% of its net assets in a portfolio of equity and debt securities of infrastructure companies, including energy infrastructure companies, industrial infrastructure companies, sustainable infrastructure companies, and technology & communication infrastructure companies.

Share on Social Networks: